A5101694996- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Diabetes Treatment and Management
- Blood Pressure and Hypertension Studies
- Cardiac Structural Anomalies and Repair
- Coronary Interventions and Diagnostics
- Erythropoietin and Anemia Treatment
- Potassium and Related Disorders
- Cardiac pacing and defibrillation studies
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiovascular and exercise physiology
- Frailty in Older Adults
- Iron Metabolism and Disorders
- Cardiac Valve Diseases and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Mechanical Circulatory Support Devices
- Dialysis and Renal Disease Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrest and Resuscitation
- Nutrition and Health in Aging
- Hormonal Regulation and Hypertension
- Antiplatelet Therapy and Cardiovascular Diseases
Hospital Clínico Universitario de Valencia
2016-2025
Centro de Investigación en Red en Enfermedades Cardiovasculares
2017-2025
Universitat de València
2016-2025
INCLIVA Health Research Institute
2013-2025
Centro de Investigación Biomédica en Red
2017-2024
Hospital Universitario Virgen de la Arrixaca
2023
Universidad Católica de Honduras Nuestra Señora Reina de la Paz
2022
University of Washington
2017
Instituto de Salud Carlos III
2017
University of Regensburg
2013
Increasing the patient's heart rate (HR) has emerged as a therapeutic option in patients with failure preserved ejection fraction (HFpEF). However, evidence is conflicting, and profile of who benefit most from this strategy remains unclear.
Background: The prognostic value of long-term potassium monitoring and dynamics in heart failure has not been characterized completely. We sought to determine the association between serum values collected at follow-up with all-cause mortality a prospective consecutive cohort patients discharged from previous acute admission. Methods: Serum was measured every physician-patient encounter, including hospital admissions ambulatory settings. multivariable-adjusted assessed by using comprehensive...
Importance The MOSCA-FRAIL randomized clinical trial compared invasive and conservative treatment strategies in patients with frailty non–ST-segment elevation myocardial infarction (NSTEMI). It showed no differences the number of days alive out hospital at 1 year. Objective To assess outcomes during extended follow-up. Design, Setting, Participants was conducted 13 hospitals Spain between July 7, 2017, January 9, 2021, included 167 adults (aged ≥70 years) (Clinical Frailty Scale score ≥4)...
AimElevated brain natriuretic peptide (BNP) and tumour marker antigen carbohydrate 125 (CA125) levels have shown to be associated with higher risk for adverse outcomes in patients acute heart failure (AHF). Nevertheless, no attempt has been made explore the utility of combining these two biomarkers. We sought assess whether CA125 adds prognostic value BNP predicting 6-month all-cause mortality AHF.
Heart failure with preserved ejection fraction (HFpEF) is remarkably common in elderly people highly prevalent comorbid conditions. Despite its increasing prevalence, there no evidence-based effective therapy for HFpEF. We sought to evaluate whether inspiratory muscle training (IMT) improves exercise capacity, as well left ventricular diastolic function, biomarker profile and quality of life (QoL) patients advanced HFpEF nonreduced maximal pressure (MIP).A total 26 (median (interquartile...
Background— Differences in hospital staffing may influence outcomes for patients with acute conditions, including heart failure (HF), depending on which day of the week are admitted. This study examined relationship between hospitalized HF and death rate, length stay (LOS), rehospitalization rate. Methods Results— A total 259 US hospitals participating Organized Program to Initiate Lifesaving Treatment Hospitalized Patients With Heart Failure (OPTIMIZE-HF) submitted data 48 612 HF. Sixty-...
Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit using longitudinal values, how this predictive ability modified when modelling together. The aim study was to determine mutually-adjusted association between trajectories NT-proBNP CA125 with after an episode AHF.We included 946 consecutive patients...